BC Week In Review | Dec 20, 2010
Clinical News

GGF2: Phase I started

Acorda began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial evaluating IV GGF2 in about 50 patients. Acorda gained rights to GGF2 from CeNes Pharmaceuticals plc, which was acquired by Paion in 2008 (see BioCentury,...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BC Week In Review | Nov 10, 2008
Clinical News

M6G: Data

A meta-analysis of 2 Phase II trials and 2 Phase III trials in a total of 769 patients showed that M6G significantly reduced vomiting and nausea compared with morphine (p=0.01 and p=0.025, respectively). Paion said...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

Shaking in their shortsA handful of heavily shorted small cap biotechs got a bounce last week after the U.S. Securities and Exchange Commission announced new actions intended to eliminate "naked" short selling - the abusive practice...
BC Week In Review | Aug 4, 2008
Clinical News

Acorda, Paion preclinical data

In a rat model of CHF, GGF2 showed sustained improvement in cardiac function for 10 days following treatment. GGF2 also achieved therapeutic effect with dosing every 48 or 96 hours. Acorda plans to submit an...
BC Week In Review | Jul 14, 2008
Clinical News

CNS 7056: Phase I start

This year, Paion will begin a double-blind, placebo- and midazolam-controlled, U.S. Phase I trial to evaluate intravenous CNS 7056 in 40-90 healthy volunteers. The company acquired CNS 7056 earlier this year through its acquisition of...
BioCentury | Jul 7, 2008
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1Q08 oper loss 4/2/08 Genitope (NASDAQ:GTOP) 89% to ~20 $12.4 0.06 3/31/08 $52.1 Seeking strategic alternatives, including the possible sale of its MyVax...
BC Week In Review | Jun 30, 2008
Company News

CeNeS, Paion deal

Paion completed its previously announced acquisition of CeNeS for about 7.9 million shares, or €11.1 million ($17.1 million) based on Paion’s closing price of €1.41 on June 20, the last day of trading before the...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

Invitrogen needs uplift By Stacy Lawrence Senior Writer Despite the prospect of creating a mammoth provider of reagents and systems via the acquisition of Applied Biosystems (NYSE:ABI), investors in Invitrogen (NASDAQ:IVGN) seemed uncertain about how...
BC Week In Review | Jun 2, 2008
Company News

CeNeS, GlaxoSmithKline deal

CeNeS will issue 120,752 shares to GlaxoSmithKline as part of a 2003 deal under which CeNeS acquired CNS 7056 and associated compounds from the pharma company. The payment is valued at £36,000 ($71,800) based on...
Items per page:
1 - 10 of 210
BC Week In Review | Dec 20, 2010
Clinical News

GGF2: Phase I started

Acorda began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial evaluating IV GGF2 in about 50 patients. Acorda gained rights to GGF2 from CeNes Pharmaceuticals plc, which was acquired by Paion in 2008 (see BioCentury,...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BC Week In Review | Nov 10, 2008
Clinical News

M6G: Data

A meta-analysis of 2 Phase II trials and 2 Phase III trials in a total of 769 patients showed that M6G significantly reduced vomiting and nausea compared with morphine (p=0.01 and p=0.025, respectively). Paion said...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

Shaking in their shortsA handful of heavily shorted small cap biotechs got a bounce last week after the U.S. Securities and Exchange Commission announced new actions intended to eliminate "naked" short selling - the abusive practice...
BC Week In Review | Aug 4, 2008
Clinical News

Acorda, Paion preclinical data

In a rat model of CHF, GGF2 showed sustained improvement in cardiac function for 10 days following treatment. GGF2 also achieved therapeutic effect with dosing every 48 or 96 hours. Acorda plans to submit an...
BC Week In Review | Jul 14, 2008
Clinical News

CNS 7056: Phase I start

This year, Paion will begin a double-blind, placebo- and midazolam-controlled, U.S. Phase I trial to evaluate intravenous CNS 7056 in 40-90 healthy volunteers. The company acquired CNS 7056 earlier this year through its acquisition of...
BioCentury | Jul 7, 2008
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1Q08 oper loss 4/2/08 Genitope (NASDAQ:GTOP) 89% to ~20 $12.4 0.06 3/31/08 $52.1 Seeking strategic alternatives, including the possible sale of its MyVax...
BC Week In Review | Jun 30, 2008
Company News

CeNeS, Paion deal

Paion completed its previously announced acquisition of CeNeS for about 7.9 million shares, or €11.1 million ($17.1 million) based on Paion’s closing price of €1.41 on June 20, the last day of trading before the...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

Invitrogen needs uplift By Stacy Lawrence Senior Writer Despite the prospect of creating a mammoth provider of reagents and systems via the acquisition of Applied Biosystems (NYSE:ABI), investors in Invitrogen (NASDAQ:IVGN) seemed uncertain about how...
BC Week In Review | Jun 2, 2008
Company News

CeNeS, GlaxoSmithKline deal

CeNeS will issue 120,752 shares to GlaxoSmithKline as part of a 2003 deal under which CeNeS acquired CNS 7056 and associated compounds from the pharma company. The payment is valued at £36,000 ($71,800) based on...
Items per page:
1 - 10 of 210